

MicroRNA-155 Is Required for Effector CD8⁺ T Cell Responses to Virus Infection and Cancer

Jan C. Dudda,^{1,7} Bruno Salaun,^{1,7} Yun Ji,^{2,6,7} Douglas C. Palmer,² Gwennaelle C. Monnot,¹ Estelle Merck,¹ Caroline Boudousquie,¹ Daniel T. Utzschneider,⁴ Thelma M. Escobar,³ Rachel Perret,¹ Stefan A. Muljo,³ Michael Hebeisen,^{1,5} Nathalie Rufer,^{1,5} Dietmar Zehn,⁴ Alena Donda,¹ Nicholas P. Restifo,² Werner Held,¹ Luca Gattinoni,^{2,6,7} and Pedro Romero^{1,7,*}

¹Ludwig Center for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland

²Center for Cancer Research, National Cancer Institute

³Laboratory of Immunology, National Institute of Allergy and Infectious Diseases National Institutes of Health (NIH), Bethesda, MD 20892, USA

⁴Swiss Vaccine Research Institute

⁵Department of Research

University Hospital, 1011 Lausanne, Switzerland

⁶Present address: Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA

⁷These authors contributed equally to this work

*Correspondence: pedro.romero@unil.ch

<http://dx.doi.org/10.1016/j.immuni.2012.12.006>

SUMMARY

MicroRNAs (miRNAs) regulate the function of several immune cells, but their role in promoting CD8⁺ T cell immunity remains unknown. Here we report that miRNA-155 is required for CD8⁺ T cell responses to both virus and cancer. In the absence of miRNA-155, accumulation of effector CD8⁺ T cells was severely reduced during acute and chronic viral infections and control of virus replication was impaired. Similarly, *Mir155*^{-/-} CD8⁺ T cells were ineffective at controlling tumor growth, whereas miRNA-155 overexpression enhanced the antitumor response. miRNA-155 deficiency resulted in accumulation of suppressor of cytokine signaling-1 (SOCS-1) causing defective cytokine signaling through STAT5. Consistently, enforced expression of SOCS-1 in CD8⁺ T cells phenocopied the miRNA-155 deficiency, whereas SOCS-1 silencing augmented tumor destruction. These findings identify miRNA-155 and its target SOCS-1 as key regulators of effector CD8⁺ T cells that can be modulated to potentiate immunotherapies for infectious diseases and cancer.

INTRODUCTION

CD8⁺ T cells are essential effectors in immune responses to intracellular pathogens and cancer (Zhang and Bevan, 2011). Upon stimulation, antigen-specific CD8⁺ T cells massively expand and differentiate into inflammatory cytokine producing, cytolytic T cells able to eliminate virally infected or transformed cells. As the antigen is cleared, the majority of specific CD8⁺ effector T cells die (Marrack and Kappler, 2004), whereas only a small number of memory cells survive. The CD8⁺ T cell

response is influenced by a series of costimulatory (and inhibitory) ligands and by multiple soluble mediators such as interleukin-2 (IL-2) (Boyman and Sprent, 2012). The latter is essential for sustaining an efficient effector response, whereas other cytokines such as IL-7 and IL-15 play crucial roles for the survival of naive or memory T cells (Cui and Kaech, 2010). Several studies have identified key molecular factors involved in the differentiation from naive to effector CD8⁺ T cells, but the contribution of microRNAs (miRNAs) has just begun to be investigated (Almanza et al., 2010).

miRNAs are a class of small, noncoding RNAs that impart posttranscriptional gene regulation (Bartel, 2004) through several mechanisms including translational repression and messenger RNA (mRNA) degradation (Djuranovic et al., 2011). They are important in many physiological processes, in carcinogenesis (Calin and Croce, 2006), and in the immune system (Xiao and Rajewsky, 2009). Early studies in mice deficient for Dicer, an RNase III enzyme important for mature miRNA production, revealed that miRNAs are involved in CD4⁺ T cell differentiation and strongly influence CD8⁺ T cell responses (Muljo et al., 2005; Zhang and Bevan, 2010). Specific miRNAs were shown to regulate both lymphocyte development and function. For instance, miRNA-181a influences thymocyte selection by modulating the expression of molecules involved in T cell receptor (TCR) signaling (Li et al., 2007). Moreover, the miRNA-17~92 cluster regulates B cell development (Ventura et al., 2008), autoimmunity, and T helper 1 (Th1) cell differentiation (Jiang et al., 2011; Xiao et al., 2008).

miRNA-155 is upregulated upon lymphocyte activation (Haasch et al., 2002) to control cell proliferation and differentiation (O'Connell et al., 2008; Turner and Vigorito, 2008). For instance, miRNA-155 regulates B cell proliferation, malignancy, and antibody production, at least in part through inhibition of activation-induced cytidine deaminase and PU.1 expression (Rodriguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007). In CD4⁺ T cells, miRNA-155 has been shown to suppress differentiation of naive cells into Th2 by downregulation of c-Maf, to promote Th17 cell-mediated inflammation (Kurowska-Stolarska




Figure 1. miRNA-155 Expression Is Regulated at Various Stages of CD8⁺ T Cell Differentiation in a TCR-Affinity-Dependent Manner

(A) Quantification of miRNA-155 in human CD8⁺ T cells transduced with TCRs of increasing affinity following TCR stimulation with multimers ($n = 3$ experiments) as fold increase relative to unstimulated clones.

(B) miRNA-155 expression of naive mouse OT-1 T cells stimulated with splenic dendritic cells pulsed with the natural SIINFEKL (N4) or weaker SIITFEKL (T4) altered peptide ligand as relative to day 0 unstimulated cells. Data are representative for triplicates in one out of two experiments.

(C) miRNA-155 concentrations in naive, central memory, and effector CD8⁺ T cells sorted at day 8 after LCMV WE infection as fold change relative to naive cells.

(D) Relative miRNA-155 expression in splenic naive and effector CD8⁺ T cells sorted from LCMV-infected mice. Symbols represent individual mice and the line is the mean \pm SEM. Data are representative for two independent experiments. For human BIC expression, also see Figure S1.

et al., 2011; O'Connell et al., 2010) and to inhibit interferon- γ R (IFN- γ R) expression (Banerjee et al., 2010; Martinez-Nunez et al., 2011). In addition to direct modulation of cytokine receptor expression, miRNA-155 shapes cytokine signaling in several cell subsets via downregulation of SMAD2 (Louafi et al., 2010) and suppressor of cytokine signaling (SOCS-1) (Lu et al., 2009; O'Connell et al., 2010; Wang et al., 2010). Despite the evidence for an important role of miRNA-155 in a wide spectrum of immune compartments, it is not known whether this miRNA, which is highly expressed in antigen-experienced CD8⁺ T cells (Salaun et al., 2011), influences CD8⁺ T cells in vivo. In the present study, we have investigated the role of miRNA-155 during CD8⁺ T cell responses to viral infection, vaccination, and cancer.

RESULTS

CD8⁺ T Cells Dynamically Regulate miRNA-155 Depending on the Magnitude of TCR Stimulation or Their Differentiation State

The strength of TCR signaling has a major impact on the magnitude of CD8⁺ T cell expansion, but not on their differentiation (Zehn et al., 2009). We sought to investigate whether the strength of TCR stimulation affects the expression of miRNA-155 in CD8⁺ T cells by transducing human CD8⁺ T cells with variants of a NY-ESO-1-specific TCR of increasing affinity for its ligand (Derré et al., 2008; Schmid et al., 2010). Comparatively, a mutated low-affinity TCR failed to upregulate miRNA-155 within 48 hr, whereas TCR variants of higher affinities induced higher levels of miRNA-155 than the wild-type (WT) (Figure 1A). Thus, miRNA-155 expression increased in a TCR affinity-dependent manner in human CD8⁺ T cells. A similar upregulation was

observed for the pri-miRNA-155 noncoding RNA transcript, BIC (see Figure S1 available online). To see whether miRNA-155 was also regulated in an affinity-dependent manner in mouse CD8⁺ T cells, we activated naive OT-1 T cells with splenic dendritic cells (DC) loaded with the WT peptide SIINFEKL (N4) or the weaker altered peptide ligand SIITFEKL (T4) (Daniels et al., 2006). To exclude miRNA-155 contamination from the DCs, we used *Mir155*^{-/-} DCs, which retain normal antigen-presenting capabilities (O'Connell et al., 2010). Exposure of OT-1 cells to the WT natural peptide resulted in a strong upregulation of miRNA-155, whereas a weaker TCR stimulation by the T4 peptide was less effective (Figure 1B). To assess miRNA-155 regulation in vivo, we analyzed naive (CD62L⁺CD44⁻), effector (CD62L⁻CD44⁺) and central memory (CD62L⁺CD44⁺) CD8⁺ T cells following lymphocytic choriomeningitis virus (LCMV) infection (200 pfu of WE strain). Compared to their naive counterparts, miRNA-155 was strongly upregulated in effector cells and to a lower extent in central memory CD8⁺ T cells 8 days postinfection (Figure 1C). A more detailed kinetics of miRNA-155 regulation during LCMV infection revealed that numbers of effector cells peaked on day 6 but stayed low in naive cells (Figure 1D). These results demonstrate that miRNA-155 is induced in effector CD8⁺ T cells depending on the strength of stimulation and differentiation.

miRNA-155 Promotes the Accumulation of Anti-Viral Effector and Central Memory CD8⁺ T Cells

To determine the role of miRNA-155 in activated CD8⁺ T cells, we monitored the expansion of effector cells following acute LCMV WE strain infection in the presence or absence of miRNA-155. Percentage, number, and phenotype of naive *Mir155*^{-/-} CD8⁺




Figure 2. miRNA-155 Is Required for Optimal Effector CD8⁺ T Cell Accumulation and Memory Cell Differentiation during Acute LCMV Infection

(A) Splenocytes from day 8 infected WT and *Mir155*^{-/-} mice were stained with K^b/LCMV gp33 tetramers and anti-CD8α. (B) Blood percentages and numbers of CD8⁺ (upper panels) and gp33 tetramer⁺ cells (lower panels) on day 8 of infection. (C) Percentages of CD44^{hi}CD62L^{lo} effector CD8⁺ T cells gated on lymphocytes in WT and *Mir155*^{-/-} spleen cells (upper) and of gp33 tetramer⁺ cells within the CD8⁺ T cells (lower panel) at days 6 to 8. (D) Percentages of total CD8⁺ T cells (left) and CD127^{hi} cells within tetramer gp33⁺ CD8⁺ cells (right panel) in blood at given time points. (E) Percentage of liver CD127^{hi}CD62L^{hi} tetramer gp33 and np396⁺ memory cells and (F) IL-2 production upon gp33 peptide restimulation of splenocytes within IFN-γ-positive CD8⁺ T cells at 3 months past infection. Symbols represent individual mice, and the line is the mean ± SEM. Representative results of one out of four (A–C) to two (D–F) independent experiments with three to five mice are pictured. Also see Figure S2.

T cells in blood and spleen did not differ from those in WT mice before infection (Figure S2A; data not shown). In contrast, both percentage and number of total CD8⁺ T cells, as well as virus gp33 tetramer specific CD8⁺ effector T cells, were substantially reduced in spleen and blood of *Mir155*^{-/-} mice at the peak of

the response (Figures 2A and 2B). Following the expansion of CD44⁺ effector cells in the blood and spleen from days 6 to 8, we observed impaired effector CD8⁺ cell accumulation in spleen, liver, and blood of *Mir155*^{-/-} mice (Figure 2C; data not shown). Despite a defect in the magnitude of effector T cell responses,




Figure 3. A Cell Intrinsic Role for miRNA-155 in Promoting Effector CD8⁺ T Cells

(A) Congenically marked WT and *Mir155*^{-/-} OT-1 cells were competitively cocultured with peptide-pulsed dendritic cells, and the ratio of populations is pictured at indicated time points (left). On day 5, percentage of trypan blue cells harvested from either WT or *Mir155*^{-/-} cultures was counted (right graph). Pooled data from three representative experiments are pictured.

(B) CD8⁺ T cells from WT and *Mir155*^{-/-} mice were cotransferred into WT or deficient hosts before LCMV WE infection, and percentages in blood at day 8 were measured.

(C) A 1:1 mix of WT and *Mir155*^{-/-} splenocytes was adoptively transferred into Rag2 and IL2R γ double deficient mice, which were infected with LCMV WE 2 months after transfer. CD8⁺ effector T cell ratios at days -1 and 8 postinfection are pictured.

(D) Proliferating BrdU-positive splenic CD44^{hi} CD8⁺ effector T cells at days 6 and 7 postinfection. (E and F) At the same time, (E) cells were stained for the proliferation marker Ki67 (day 7) and (F) apoptotic cells were identified by AnnexinV staining. Symbols represent individual mice, and the line is the mean \pm SEM. Representative results from two (B and C) to three (D–F) experiments are pictured.

Intrinsic Expression of miRNA-155 in CD8⁺ T Cells Promotes Proliferation and Limits Apoptosis of Effector CD8⁺ T Cells

To investigate whether the defective expansion of CD8⁺ T cells was cell intrinsic, we cocultured naive WT and congenic *Mir155*^{-/-} OT-1 CD8⁺ T cells

Mir155^{-/-} animals were capable of controlling viral replication and clearing the virus (Figure S2B), as also confirmed by the lack of CD44 upregulation on adoptively transferred naive LCMV-specific P14 T cells (Figure S2C). In line with this result, CD8⁺ T cells differentiated into phenotypically and functionally cytolytic effector cells similar to WT cells during LCMV infection (Figures S2A, S2D, and S2E). Interestingly, circulating T cells in *Mir155*^{-/-} mice exhibited not only a defect in the expansion at the peak of the immune response but also a more rapid contraction compared to WT animals (Figure 2D). Moreover, CD127⁺ CD62L⁺ KLRG1⁻ memory cells were strongly reduced in the gp33 and np396 tetramer⁺ CD8⁺ T cells in blood, liver, and spleen of *Mir155*^{-/-} mice 3 months after infection (Figure 2E; Figure S2F; data not shown). Consistent with these findings, IL-2 production, a hallmark of central memory cells, was strongly diminished in *Mir155*^{-/-} mice after stimulation with gp33 peptide (Figure 2F; Figure S2F). In this immune memory context, it is of interest that we observed a deficient CD4⁺ effector T cell activation on day 8 of the response in *Mir155*^{-/-} mice (data not shown). Altogether, these results demonstrate that miRNA-155 is crucial for a robust T cell expansion, but not effector functions, as well as for a memory phenotype response upon an acute LCMV infection.

together with peptide pulsed dendritic cells and analyzed the OT-1 cell ratio. After 5 days, WT CD8⁺ T cells outnumbered *Mir155*^{-/-} cells and the abundance of dead cells was strongly increased among *Mir155*^{-/-} T cells (Figure 3A). To assess these parameters in vivo, we cotransferred equal numbers of congenic polyclonal WT and *Mir155*^{-/-} CD8⁺ T cells into either WT or *Mir155*^{-/-} hosts, which were then infected with LCMV. Despite the initial low frequency of WT CD8⁺ T cells transferred in miRNA-155 ablated hosts (about 1% of CD8⁺ T cells in blood before infection), these cells expanded to about 30% of the CD8⁺ T cells at the peak of the response. In contrast, the frequency of *Mir155*^{-/-} CD8⁺ T cells that transferred into WT hosts decreased upon infection (Figure 3B), clearly demonstrating a stronger response of WT compared to *Mir155*^{-/-} CD8⁺ T cells. When Rag2 and γ common (γ c) chain deficient hosts were engrafted with a 1:1 mix of WT and *Mir155*^{-/-} splenocytes, both populations reached similar frequencies after 2 months, indicating comparable homeostatic expansion (Figure 3C). However, following LCMV infection, WT T cells again showed an advantage in expansion over their *Mir155*^{-/-} counterparts. To determine the basis for the impaired accumulation of virus-specific CD8⁺ T cells in the absence of miRNA-155, we pulsed LCMV infected WT and *Mir155*^{-/-} mice with bromodeoxyuridine (BrdU)




Figure 4. miRNA-155 Drives Survival of Effector Cells and Sustains the Anti-Viral Response in a Chronic LCMV Infection

WT and *Mir155*^{-/-} mice were infected with LCMV clone 13 and phenotype and expansion of effector cells was monitored by flow cytometry. (A) Effector CD44^{hi}CD62L^{lo} within blood CD8⁺ T cells at indicated time points.

(B and C) At 5 weeks, splenic CD8⁺ cells were analyzed for the indicated activation markers and gp33 tetramer⁺ cells shown as (B) flow cytometry dot blots from representative mice and (C) graph from one representative out of three experiments. (D) Virus titer and (E) cytokine response upon stimulation with a peptide cocktail was determined in the blood at 2 and 3 months after infection, respectively.

(F) Weight of mice was monitored the first 2 weeks postinfection. Symbols represent individual mice, and the line is the mean (C and D). Error bars are given as \pm SEM. Shown are representative results from one out of two experiments with three to five mice per group.

antigen exposure, which characterizes chronic infections and cancer. Mice were inoculated with 2×10^6 pfu of LCMV clone 13, causing a chronic infection for several weeks (Moskophidis et al., 1993; Salvato et al., 1991). Whereas WT mice mounted a robust effector CD8⁺ T cell response with high percentages of CD44⁺CD62L⁻ effector cells that were maintained over time, *Mir155*^{-/-} mice progressively lost effector CD8⁺ T cells (Figure 4A). Interestingly, the remaining CD44⁺ cells in spleen showed high CD127 and CD62L expression, reminiscent of a memory phenotype (Figure 4B). Percentages and numbers of gp33 tetramer-positive cells were also strongly

and measured proliferation and apoptosis 4 hr later. We found that the proliferation of *Mir155*^{-/-} CD44⁺ effector CD8⁺ T cells was decreased compared to WT cells 6 days after infection (Figure 3D). Additionally, the frequency of proliferating Ki67⁺ cells within the CD44⁺CD62L⁻ effector CD8⁺ T cells was reduced in *Mir155*^{-/-} mice (Figure 3E). Finally, we observed an increased frequency of AnnexinV⁺ apoptotic cells in *Mir155*^{-/-} compared to WT effector CD8⁺ T cells 7 days after infection (Figure 3F). Altogether, these data demonstrate a cell-intrinsic role of miRNA-155 in the proliferation and survival of effector CD8⁺ T cells in response to LCMV infection, but not for homeostatic expansion in lymphopenic hosts.

miRNA-155 Is Crucial for Effector CD8⁺ T Cell Accumulation and Virus Control in Chronic LCMV Infection

On the basis of the strong impairment of effector CD8⁺ T cell accumulation in low dose LCMV infection, we asked how *Mir155*^{-/-} mice would respond to high dose and long-lasting

decreased in deficient mice 5 weeks and 3 months postinfection (Figures 4B and 4C; data not shown). At this time, we could not detect cells capable of producing effector cytokines in response to a cocktail of LCMV peptides in miRNA-155 ablated mice, confirming the loss of most virus-specific *Mir155*^{-/-} CD8⁺ T cells and ruling out TCR downregulation that may appear as tetramer-negative T cells (Figure 4E; data not shown). Whereas about 50% of WT cells remained positive for PD-1, associated with T cell exhaustion, PD-1 was barely detectable on *Mir155*^{-/-} CD8⁺ T cells 5 weeks after infection (Figure 4C). Importantly, virus titers were elevated 5 weeks and 2 months postinfection in miRNA-155 ablated mice (Figure 4D; data not shown). Finally, WT but not miRNA-155 ablated mice showed symptoms of immunopathology such as shivering, hunching, and weight loss, suggesting a lower inflammatory response in the absence of miRNA-155 (Figure 4F; data not shown). These data demonstrate an important role of miRNA-155 in maintenance and survival of CD8⁺ effector T cells, as well as virus control in chronic virus infections.




Figure 5. miRNA-155 Is Crucial for the CD8⁺ T Cell Response to Peptide Vaccination and Tumor Challenge

(A) Congenically marked OT-1 and polyclonal CD8⁺ T cells from WT or *Mir155*^{-/-} backgrounds were transferred into WT hosts, which were immunized with OVA peptide and CpG in IFA. Shown is the ratio of antigen-specific versus polyclonal cells in the draining lymph nodes 4 days later. Symbols represent individual mice, and the line is the mean ± SEM.

(B) Ratio of blood WT and *Mir155*^{-/-} OT-1 CD8⁺ T cells cotransferred into WT hosts, which were immunized as in (A) on day 7. Symbols represent individual mice, and the line is the mean ± SEM. Data from one out of two (A) to three (B) independent experiments are pictured.

(C and D) Upon adoptive transfer of WT or *Mir155*^{-/-} OT-1 cells, mice were engrafted with B16 melanoma cells expressing OVA and immunized 1 week later. Tumor growth (C) and survival (D) are pictured (n = 5–9 mice per group, data from one out of two independent experiments) displayed as mean ± SEM.

(E and F) TCR transgenic pmel CD8⁺ T over-expressing miRNA-155 or control scrambled miRNA were transferred into B16 tumor-bearing mice and (E) tumor growth and (F) survival of mice are shown from one representative out of two experiments with five to eight mice per group displayed as mean ± SEM. Also see Figure S3.

miRNA-155 Expression in CD8⁺ T Cells Is Crucial for Efficient Immunization and Cancer Immunotherapy

Because we observed an important role of miRNA-155 to sustain CD8⁺ T cell responses to chronic infection, we looked at the impact of miRNA-155 on CD8⁺ T cell-dependent antitumor immunity, which requires robust CD8⁺ T cell responses. We examined the role of miRNA-155 in CD8⁺ T cells for vaccination, a clinically relevant setting characterized by limited adjuvant-induced inflammation. Polyclonal and OVA-specific OT-1 CD8⁺ T cells (either WT or *Mir155*^{-/-}) were cotransferred into WT mice before immunization with OVA peptide adjuvanted with IFA and CpG-ODNs. While the ratio of WT OT-1 to polyclonal cells strongly increased following immunization, there was only a minor increment in the ratio of *Mir155*^{-/-} OT-1 to polyclonal WT cells (Figure 5A). We next cotransferred OT-1 cells from both WT and *Mir155*^{-/-} backgrounds into WT mice before immunization. WT and *Mir155*^{-/-} cells were found in similar proportions indicating a comparable survival after adoptive transfer. Following immunization, however, WT cells accumulated more efficiently than *Mir155*^{-/-} cells (Figure 5B), whereas upregulation of CD44 and the proportion of cells producing IFN-γ were comparable (Figures S3A and S3B). Now we were interested to see

whether miRNA-155 would also be critical for tumor control by CD8⁺ T cells and engrafted B16 melanoma upon transfer of naive WT or *Mir155*^{-/-} OT-1 T cells and therapeutic vaccination 1 week later. Compared to WT, *Mir155*^{-/-} CD8⁺ T cells were less effective in inhibiting tumor growth and ensuring the survival of tumor-challenged mice (Figures 5C and 3D). Given the inability of T cells to expand and control tumor growth in the absence of miRNA-155, we hypothesized that enforcing miRNA-155 expression would augment the antitumor activity of CD8⁺ T cells. Pmel-1 TCR transgenic CD8⁺ T cells specific for the melanoma antigen gp100 were transduced with a retrovirus encoding miRNA-155 or scrambled miRNA and adoptively transferred into tumor-bearing mice in conjunction with gp100 vaccination and IL-2. There were no phenotypic differences between control and miRNA-155 overexpressing T cells prior to adoptive transfer (Figure S3C). However, overexpression of miRNA-155 greatly enhanced the antitumor responses compared to scrambled miRNA control (Figure 5E). Notably, 80% of mice receiving miRNA-155 transduced T cells survived for over 60 days, whereas all mice treated with control cells or left untreated had to be euthanized after less than 40 days due to tumor size (Figure 5F). Taken together, these results show that upon vaccination, *Mir155*^{-/-} CD8⁺ T cells differentiated into effector cells but failed to accumulate in normal numbers. Consequently, the antitumor response was strongly dependent on miRNA-155 and could be therapeutically boosted by enforced miRNA-155 expression.




Figure 6. SOCS-1 and miRNA-155 Modulate the Antiviral CD8⁺ T Cell Response and Cytokine Signaling

(A) SOCS-1 mRNA concentrations were measured upon LCMV WE infection in purified effector (CD44^{hi}CD62L^{lo}) WT and *Mir155*^{-/-} splenic CD8⁺ T cells by qPCR relative to naive CD8⁺ T cells from noninfected mice.

(B and C) Regulation of SOCS-1 by miRNA-155 in naive CD8⁺ T cells from WT and miRNA-155 deleted mice, as well as after retroviral transfection with miRNA-155 overexpressing or control vectors, was tested by (B) qPCR (shown as relative to β -actin) and (C) immunoblot.

(D) Naive or effector T cells from LCMV-infected mice were stimulated with indicated cytokines, and pSTAT5 was measured by flow cytometry.

(E) WT and *Mir155*^{-/-} T cells were transduced with control or shSOCS-1 lentivirus and pSTAT5 response to IL-2 is shown. The table gives the percentages of MFI normalized to the MFI measured in WT sh-control cells set to 100%. Representative data from two (A–C) to three (D and E) experiments are pictured as mean \pm SEM. Also see Figure S4.

Targeting of SOCS-1 by miRNA-155 in Effector CD8⁺ T Cells Enables Cytokine Responsiveness and Accumulation

miRNA-155 has been shown to regulate γ c chain cytokine signaling by targeting SOCS-1 expression (D’Souza and Lefrançois, 2003; Lu et al., 2009; Wang et al., 2010). We assessed

SOCS-1 regulation in splenic effector CD44⁺CD62L⁻CD8⁺ T cells during the response to acute LCMV infection of WT and *Mir155*^{-/-} mice. We found that both WT and *Mir155*^{-/-} CD8⁺ T cells downregulated SOCS-1 on days 6 and 8 compared to CD62L⁺CD44⁻ naive CD8⁺ T cells from noninfected mice (Figure 6A). To more directly test whether SOCS-1 was regulated




Figure 7. SOCS-1 Limits the CD8⁺ T Cell Response to Virus and Cancer

(A) TCR transgenic P14 CD8⁺ T cells overexpressing SOCS-1 (P14xSOCS-1) or not were adoptively transferred before LCMV WE infection. Data show the percentage of transferred cells in the lymphocyte gate at days 6, 7, and 8 post-infection as mean \pm SEM.

(B) Apoptotic cells within P14 T cells 7 days after infection. Symbols represent single mice, and the line is the mean.

(C and D) TCR transgenic pmel CD8⁺ T cells were transduced with a retrovirus encoding for a scrambled control or shSOCS-1 mRNA and adoptively transferred into tumor-bearing mice. (C) Absolute numbers of donor CD8⁺ T cells were determined in spleen at days 4 to 6 after adoptive transfer and (D) tumor size of mice was monitored. Data are from one representative out of two independent experiments with two (C) to five mice (D) per group and displayed as mean \pm SEM. Please also see Figure S5.

by miRNA-155, we measured SOCS-1 mRNA in WT and *Mir155*^{-/-} CD8⁺ T cells, as well as in cells overexpressing miRNA-155 or scrambled control miRNA. We found that the amounts of SOCS-1 transcripts were inversely related to the cellular content of miRNA-155, with the highest concentration of SOCS-1 in *Mir155*^{-/-} cells and the lowest in miRNA-155 transduced cells (Figure 6B). These results were further confirmed at the protein level, indicating that miRNA-155 is a critical regulator of SOCS-1 translation in CD8⁺ T cells (Figure 6C). To test whether the loss of miRNA-155 impaired γ c chain cytokine signaling in CD8⁺ T cells by upregulating SOCS-1, we compared STAT5 phosphorylation in response to IL-2, IL-7, or IL-15 in WT and *Mir155*^{-/-} cells. Stimulation of naive and effector CD8⁺ T cells isolated 8 days after LCMV infection resulted in a limited phosphorylation of STAT5 in miRNA-155 ablated cells, demonstrating an impaired cytokine signaling (Figure 6D). Diminished STAT5 phosphorylation was not due to differential expression of the cytokine receptor chains CD25, CD122, CD127, or CD132 (Figure S4). To further investigate whether the impaired cytokine signaling was dependent on the higher SOCS-1 concentration in *Mir155*^{-/-} CD8⁺ T cells, we transduced WT and *Mir155*^{-/-} CD8⁺ T cells with control or shSOCS-1 lentivirus. Although in vitro activation of T cells diminished the impact of miRNA-155 on cytokine signaling, we consistently detected a rescue of pSTAT5 generation in shSOCS-1 transfected *Mir155*^{-/-} cells (Figure 6E). Interestingly, baseline pSTAT5 expression was already higher in WT than in *Mir155*^{-/-} cells without additional IL-2 stimulation. The difference between WT and *Mir155*^{-/-} cells was still apparent with intermediate but disappeared with high IL-2 concentrations, demonstrating that saturating amounts of IL-2 overcome the miRNA-155 and SOCS-1-dependent inhibition

and differentiation-dependent regulation of SOCS-1 during the response to LCMV and suggest that *Mir155*^{-/-} CD8⁺ T cells have impaired cytokine signaling due to increased SOCS-1.

SOCS-1 Restrains CD8⁺ T Cell Responses to Virus and Cancer

To test whether increased SOCS-1 expression recapitulated the impaired antigen-driven expansion of *Mir155*^{-/-} CD8⁺ T cells, we adoptively transferred SOCS-1 transgenic or WT P14 CD8⁺ T cells into congenic mice prior to infection with LCMV WE strain. The expansion of SOCS-1 transgenic P14 T cells in blood and spleen was reduced compared to P14 WT cells (Figure 7A; data not shown). Whereas effector phenotype, granzyme B, and cytokine production were not impaired (Figures S5A–S5C), we detected enhanced apoptosis of SOCS-1-overexpressing cells (Figure 7B), thus phenocopying *Mir155*^{-/-} CD8⁺ T cells (Figures 2 and 3; Figure S2). To test whether suppression of SOCS-1 could be therapeutically exploited to enhance the CD8⁺ T cell antitumor response, we adoptively transferred Pmel CD8⁺ T cells transduced with shSOCS-1 into tumor-bearing mice. SOCS-1 depletion by the construct was verified by immunoblot analysis (Figure S5D). An increased expansion of cells expressing shSOCS-1 was detected in the spleen on day 4 compared to control (Figure 7C), associated with profound tumor regression in mice that received shSOCS-1 transduced cells compared to untreated mice or mice treated with control cells (Figure 7D). Together, these results demonstrate that SOCS-1 is negatively regulating the effector CD8⁺ T cell response to virus and cancer and highlight the importance of SOCS-1 downregulation by miRNA-155 for efficient CD8⁺ T cell responses.

DISCUSSION

We have shown that miRNA-155 expression is essential for optimal CD8⁺ T cell responses toward virus infection, vaccination, and cancer. Interestingly, the phenotype of *Mir155*^{-/-} CD8⁺ T cells was similar to Dicer-deficient CD8⁺ T cells (Zhang and Bevan, 2010), suggesting that miRNA-155 is an important, likely nonredundant miRNA for CD8⁺ effector T cells. Recently, we and others found differential miRNA-155 expression associated with discrete differentiation stages in CD8⁺ T cells (Almanza et al., 2010; Salaun et al., 2011; Wu et al., 2007). Here, we showed that miRNA-155 is highly upregulated in effector CD8⁺ T cells responding to viral infection but at intermediate concentration in memory cells. This dynamic modulation of miRNA-155 raises the question of the nature of the regulating factors that are involved. miRNA-155 is induced by NF- κ B-dependent factors (Kliver et al., 2007) and AP-1 downstream of B and T cell receptors (Haasch et al., 2002; Yin et al., 2008). Interestingly, we observed that miRNA-155 expression was proportional to the strength of TCR signaling, suggesting that miRNA-155 provides competitive fitness to the most avid antigen-specific CD8⁺ T cells.

Whereas others reported a disadvantage of *Mir155*^{-/-} naive CD8⁺ T cells in bone-marrow chimeras (Lu et al., 2009), we found that expansion and long-term survival of naive *Mir155*^{-/-} CD8⁺ T cells transferred into lymphopenic hosts were not different from WT cells. miRNA-155 was crucial for effector CD8⁺ T cell proliferation and survival during the peak of LCMV infection, but it did not influence cell survival upon antigen clearance. In contrast to the reported role of miRNA-155 in other immune cells, CD8⁺ T cells were not affected in effector functions such as killing or cytokine production, and miRNA-155 deleted mice readily cleared low doses of LCMV. Interestingly, we detected an impaired generation of virus-specific central memory CD8⁺ T cells because most *Mir155*^{-/-} cells displayed a terminally differentiated phenotype. Whether this was due to a lack of CD4⁺ T cell help (Janssen et al., 2003; Shedlock and Shen, 2003), lower cytokine signaling due to higher SOCS-1 expression, and/or additional miRNA-155 targets will be subject of further investigation. In contrast to low-dose LCMV infection, we found that virus-specific *Mir155*^{-/-} effector cells disappeared during chronic LCMV infection by using high doses of clone 13. Under these conditions, WT CD8⁺ T cells undergo progressive attrition and display an "exhausted" phenotype with impaired effector functions and high PD-1 expression (Jin et al., 2010; Mueller and Ahmed, 2009; Wherry et al., 2003). We hypothesize that miRNA-155 is key for the survival of effector CD8⁺ T cells in conditions of long-term exposure to antigen and inflammation as found in chronic viral infections or cancer. Consistent with the impaired virus control, lack of miRNA-155 protected from LCMV-induced severe immunopathology, which is in line with reports demonstrating a pivotal role of miRNA-155 in autoimmune inflammation (Murugaiyan et al., 2011; O'Connell et al., 2010). With regard to T cell survival, miRNA-155 was shown to inhibit caspase 3 activity in Jurkat T cells (Ovcharenko et al., 2007) and FADD expression in macrophages (Tili et al., 2007). Whether the increased apoptosis of *Mir155*^{-/-} CD8⁺ T cells was due to such mechanisms remains to be determined.

In line with our results in virus infection, we demonstrate a central role for miRNA-155 in tumor-specific CD8⁺ T cells. First, the efficient accumulation of CD8⁺ T cells by vaccination with adjuvanted peptide required intrinsic miRNA-155 function, recapitulating our observations in LCMV infection. More importantly, *Mir155*^{-/-} effector cells were severely impaired in their ability to curb tumor growth. Because these cells acquired full effector functions independently of miRNA-155, the different tumor control was likely due to defect in the magnitude of tumor-specific T cells or to higher susceptibility to the suppressive tumor-microenvironment (Klebanoff et al., 2011). Conversely, overexpression of miRNA-155 greatly increased tumor killing by WT CD8⁺ T cells. This indicates that tumor-specific CD8⁺ T cell activity is directly dependent on miRNA-155 expression.

The accumulation of effector CD8⁺ T cells is influenced by the cytokine milieu; e.g., their initial expansion is promoted by γ c cytokines, which signaling is regulated by SOCS-1 (Cornish et al., 2003). More specifically, CD8⁺ effector cell accumulation in the LCMV response is reduced if cells lack γ c signaling (Decaluwe et al., 2010). Interestingly, IL-2 was found to be critical for the maintenance of effector CD8⁺ T cells in chronic LCMV infections (Bachmann et al., 2007). Here we show that miRNA-155 enhances cytokine signaling in CD8⁺ T cells by targeting SOCS-1. Consequently, *Mir155*^{-/-} naive and effector CD8⁺ T cells failed to mount physiologic levels of pSTAT5 in response to γ c cytokines. In line with in vitro experiments using CD4⁺ T cells (Lu et al., 2009), we observed strong and transient in vivo downregulation of SOCS-1 mRNA in virus-specific CD8⁺ T cells at day 6 of the response. Interestingly, this occurred in a partially miRNA-155 independent manner, whereas SOCS-1 protein concentrations of naive and effector CD8⁺ T cells were found to be clearly dependent on miRNA-155. Moreover, we did not detect an impact of miRNA-155 on pSTAT5 in response to IL-2 in the early effector response in vivo as well as after in vitro priming (data not shown), whereas the effect was pronounced in naive and late effector cells. This suggests a miRNA-155 independent mechanism allowing full cytokine signaling early in the effector response, whereas miRNA-155 is modulating cytokine signaling in naive and late effector cells, promoting their accumulation and survival. Interestingly, at the peak of the response, effector CD8⁺ T cells are reportedly dependent on IL-2 and IL-15 for sustained expansion (D'Souza and Lefrançois, 2003; Sanjabi et al., 2009). We were able to confirm a SOCS-1-dependent inhibition of cytokine signaling in *Mir155*^{-/-} T cells by transduction with a shSOCS-1 lentivirus in in vitro experiments. Although the formal proof that loss of SOCS-1 in *Mir155*^{-/-} CD8⁺ T cells in vivo would restore their function remains to be shown, the observed rescue of STAT5 phosphorylation in *Mir155*^{-/-} cells back to WT levels suggests that suppression of SOCS-1 in WT, but not *Mir155*^{-/-} T cells, caused the differences in pSTAT5 signaling. This hypothesis was further supported by our observation that virus-specific, SOCS-1 transgenic CD8⁺ T cells fully differentiated but failed to accumulate to normal numbers at the peak of the LCMV response, which mirrors the phenotype of *Mir155*^{-/-} T cells and identifies SOCS-1 as an important regulator of CD8⁺ T cell responses in vivo. Conversely, suppression of SOCS-1 in tumor-specific cells increased the accumulation of transferred cells and subsequently was highly therapeutic in limiting growth of established melanoma. Thus, although a

negative role for SOCS-1 in CD8⁺ T cell responses has been suggested before (Chong et al., 2003; Cornish et al., 2003; Davey et al., 2005; Marine et al., 1999; Palmer and Restifo, 2009), we here demonstrate a cell-intrinsic role of SOCS-1 in responses to virus and cancer. Our results of the highly dynamic regulation of SOCS-1 expression in vivo and the strong impact of SOCS-1 alterations in responses to virus and tumor suggests that a major part of the effects caused in CD8⁺ T cells by miRNA-155 deletion are due to increased SOCS-1 expression.

In summary, the results presented here identified a crucial cell-intrinsic role of miRNA-155 and its target SOCS-1 in effector CD8⁺ T cells and demonstrated that this miRNA is required for an optimal CTL response to both virus and tumor. Moreover, miRNA-155 overexpression in tumor-specific CD8⁺ T cells substantially increased their potency, thus providing strong evidence for a clinical potential in the context of therapeutic adoptive T cell transfer.

EXPERIMENTAL PROCEDURES

Mice

C57BL/6 mice were from Harlan. *Mir155*^{-/-} and *Rag2*^{-/-}*Il2rg*^{-/-}, TCR transgenic OT-1, and P14 mice bearing a transgenic TCR-specific for K^b/OVA₂₅₇₋₂₆₄ or LCMV D^b/GP₃₃₋₄₁ MHC-I/peptide complexes, respectively, were from Jackson and were bred under specific pathogen-free conditions. P14xSOCS-1 transgenic (Seki et al., 2007) and Pmel-1 transgenic mice expressing a TCR-specific for an H-2D^b-restricted CD8⁺ T cells epitope from the murine melanoma tumor antigen gp100₂₅₋₃₃ or human gp100₂₅₋₃₃ have been described (Overwijk et al., 2003). All animal experiments were conducted with the approval of the Lemmanic Animal Facility Network (RESAL), NCI (protocol SB-126) or NIAID (protocol LI-10) Animal Use and Care Committees.

Quantitative PCR

Total RNA from subsets was extracted with the miRNAVana kit (Ambion), and mature microRNAs (miRNA-155 and controls RNU44 and snoRNA202) were reverse transcribed with TaqMan RT MicroRNA Kit (Applied Biosystems) and amplified by using Universal Fast Start Rox Probe Master Mix (Roche) and microRNA assay kits in 384-well plates (Applied Biosystems) on an ABI Prism 7900 HT device (Applied Biosystems). RT-PCR for *Socs1* was performed with primers from Applied Biosystems. Gene expression was calculated relative to G6PDX.

In Vitro Priming with Dendritic Cells

T cells were purified from lymphoid tissues by using anti-CD8 α beads (Miltenyi) and cocultured with peptide pulsed *Mir155*^{-/-} DC. In competition experiments, equal numbers of WT and *Mir155*^{-/-} OT-1 CD8⁺ T cells were cocultured with WT DC.

Differential Stimulation of Human CD8⁺ T Cells and Microarray

Human T cells transduced with NY-ESO-1 TCR variants (Schmid et al., 2010) were stimulated with 0.01 μ g/ml (for miRNA-155 quantification) or 0.002 μ g/ml (for BIC microarray) NY-ESO-1₁₅₇₋₁₆₅ multimer. BIC quantification was done by Miltenyi Biotec.

LCMV Infection

Mice were infected intravenously with 200 pfu of the WE strain or 2 \times 10⁶ pfu clone 13 of LCMV. Cell counts in blood were performed with TrueCount tubes according to the manufacturer's instructions (BD). Viral titrations were performed by a standard plaque assay.

Cytokine and Cytotoxicity Assays

Splenocytes were stimulated with indicated peptides or a mix of LCMV peptides (gp33, gp70, gp92, gp118, gp276, np166, np205, np235, np396) at 5 μ M each or PMA (50 ng/mL) and Ionomycin (500 ng/mL) in the presence of GolgiStop (BD Pharmingen) for analysis in flow cytometry. Cytolytic activity

was assessed by using the chromium release assay with EL4 pulsed with 1 μ M GP₃₃₋₄₁ peptide and measured with a TopCount reader (Canberra Packard).

Adoptive Cell Transfers

Before LCMV infection, CD8⁺ T cells were purified by magnetic beads sorting (Miltenyi Biotec) and 1 \times 10⁶ purified CD8⁺ T cells were injected into the tail vein. In the P14xSOCS-1 experiments, 3 \times 10⁴ cells were injected normalized to gp33 tetramer-positive populations. For vaccination and tumor challenge, OT-1 cells were purified and 1 \times 10⁶ cells were injected intravenously 3 days before subdermal injection of 1 \times 10⁵ B16 melanoma cells expressing OVA. Seven days later, mice were vaccinated subcutaneously with 25 μ g OVA₂₅₇₋₂₆₄ peptide and 50 μ g CPG-ODN in PBS.

T Cell Transduction and Transfers into Tumor Bearing Mice

Pmel CD8⁺ T cells were stimulated with anti-CD3 (2 μ g/ml) and anti-CD28 (1 μ g/ml) for 24 hr, transduced with retrovirus expressing miRNA-155 or scrambled miRNA, and expanded for 4 days. To knock down SOCS-1, we transduced pmel CD8⁺ T cells 2 days after stimulation with lentivirus expressing shSOCS-1 or empty vector and selected in puromycin from days 4 to 7 prior to transfer into tumor-bearing hosts. We injected 10⁷ cells (miRNA-155 experiments) or 10⁶ (shSOCS-1 experiments) intravenously into mice bearing B16 tumor in conjunction with 2 \times 10⁷ pfu rvhgp100 and IL-2 (6X6e4 cu). In shSOCS-1 experiments, mice were sublethally irradiated prior to cell transfer. Tumor volumes were plotted as the product of perpendicular diameters. For rescue of pSTAT5 in miRNA-155 cells, WT and *Mir155*^{-/-} CD8⁺ T cells were transduced with lentivirus encoding shSOCS-1 or control sh and cultured for 1 week with IL-2 or IL-15 (R&D systems, 20 ng/ml) before cytokine stimulation (vector sequences upon request).

Flow Cytometry and pSTAT5 Measurements

Cells were stained with antibodies of the indicated specificities (eBioscience) or H-2 D^b/peptide-loaded MHC. PD-1 PE-Cy7 antibody was from Biolegend. For detection of pSTAT5, cells were stimulated with indicated cytokines (R&D systems) for 18 min and fixed with 0.5% formaldehyde in PBS for 15 min. Upon washing in medium containing 10% FCS, cells were permeabilized in 80% methanol for 20 min, washed, and stained with pSTAT5 antibody (BD Biosciences) and additional markers (eBiosciences). Labeled cells were analyzed on LSR-II (Becton Dickinson).

Immunoblot

Cells were lysed (Cell Signaling Technologies) and immunoblotting was performed by using Bio-Rad TGX reagents and protocols on nitrocellulose paper, incubated with antibodies against SOCS-1 (Lifespan Biosciences [Figure 6C] or Imgenex [Figure S6]) and with appropriate HRP-conjugated secondary antibodies (Cell Signaling Technologies). Blots were developed by using chemiluminescence (Pierce), gel images were captured with Gel Doc XRS (Bio-Rad), and densitometry was evaluated using Quantity One software (Bio-Rad).

Proliferation and Apoptosis Assay

Mice were injected intraperitoneally with 200 μ g BrdU, and proliferation was measured in spleen cells 1 hr (P14xSOCS-1 experiments) or 4 h (miRNA-155 experiments) later by staining with anti-BrdU and anti-ki67⁺ antibodies. Apoptotic cells were detected by staining splenocytes for AnnexinV upon 1 hr in vitro incubation at 37°C (all BD Pharmingen).

Statistics

The two-tailed Student's t test was used to compare two groups; multiple groups' comparisons were performed with one-way ANOVA corrected with Bonferroni's multiple-comparison test factor. Statistical survival differences in the tumor experiments were analyzed with the log rank test. Statistical significance is displayed as *p < 0.05, **p < 0.01, and ***p < 0.001. Data are displayed as mean and SEM if not indicated otherwise.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and can be found with this article online at <http://dx.doi.org/10.1016/j.immuni.2012.12.006>.

ACKNOWLEDGMENTS

We thank D. Labes for technical assistance and I. Luescher for providing tetramers. We also thank P. Martiat and B. Badran for critical input. J.C.D. and B.S. were supported in part by a grant from the MEDIC Foundation, R.P. by New Zealand Foundation for Research, Science and Technology, W.H. and C.B. by the Swiss National Science Foundation (SNSF). G.C.M., D.Z., and P.R. were supported in part by a Prodoc and a Sinergia grants from the SNSF. Y.J., D.C.P., N.P.R. and L.G. were supported by the Intramural Research Programs of the US NIH National Cancer Institute, Center for Cancer Research. T.M.E. and S.A.M. were supported by the Intramural Research Program of the NIH National Institute of Allergy and Infectious Diseases.

Received: April 5, 2012

Accepted: December 18, 2012

Published: April 18, 2013

REFERENCES

- Almanza, G., Fernandez, A., Volinia, S., Cortez-Gonzalez, X., Croce, C.M., and Zanetti, M. (2010). Selected microRNAs define cell fate determination of murine central memory CD8 T cells. *PLoS ONE* 5, e11243.
- Bachmann, M.F., Wolint, P., Walton, S., Schwarz, K., and Oxenius, A. (2007). Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. *Eur. J. Immunol.* 37, 1502–1512.
- Banerjee, A., Schambach, F., DeJong, C.S., Hammond, S.M., and Reiner, S.L. (2010). Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. *Eur. J. Immunol.* 40, 225–231.
- Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297.
- Boyman, O., and Sprent, J. (2012). The role of interleukin-2 during homeostasis and activation of the immune system. *Nat. Rev. Immunol.* 12, 180–190.
- Calin, G.A., and Croce, C.M. (2006). MicroRNA signatures in human cancers. *Nat. Rev. Cancer* 6, 857–866.
- Chong, M.M., Cornish, A.L., Darwiche, R., Stanley, E.G., Purton, J.F., Godfrey, D.I., Hilton, D.J., Starr, R., Alexander, W.S., and Kay, T.W. (2003). Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8+ T cell differentiation. *Immunity* 18, 475–487.
- Cornish, A.L., Chong, M.M., Davey, G.M., Darwiche, R., Nicola, N.A., Hilton, D.J., Kay, T.W., Starr, R., and Alexander, W.S. (2003). Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. *J. Biol. Chem.* 278, 22755–22761.
- Cui, W., and Kaech, S.M. (2010). Generation of effector CD8+ T cells and their conversion to memory T cells. *Immunol. Rev.* 236, 151–166.
- D'Souza, W.N., and Lefrançois, L. (2003). IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. *J. Immunol.* 171, 5727–5735.
- Daniels, M.A., Teixeira, E., Gill, J., Hausmann, B., Roubaty, D., Holmberg, K., Werlen, G., Holländer, G.A., Gascoigne, N.R., and Palmer, E. (2006). Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. *Nature* 444, 724–729.
- Davey, G.M., Starr, R., Cornish, A.L., Burghardt, J.T., Alexander, W.S., Carbone, F.R., Surh, C.D., and Heath, W.R. (2005). SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naïve CD8 T cells, limiting their autoimmune potential. *J. Exp. Med.* 202, 1099–1108.
- Decaluwe, H., Taillardet, M., Corcuff, E., Munitic, I., Law, H.K., Rocha, B., Rivière, Y., and Di Santo, J.P. (2010). Gamma(c) deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors. *Proc. Natl. Acad. Sci. USA* 107, 9311–9316.
- Derré, L., Bruyinx, M., Baumgaertner, P., Ferber, M., Schmid, D., Leimgruber, A., Zoete, V., Romero, P., Michielin, O., Speiser, D.E., and Rufer, N. (2008). Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. *Proc. Natl. Acad. Sci. USA* 105, 15010–15015.
- Djuranovic, S., Nahvi, A., and Green, R. (2011). A parsimonious model for gene regulation by miRNAs. *Science* 331, 550–553.
- Haasch, D., Chen, Y.W., Reilly, R.M., Chiou, X.G., Koterski, S., Smith, M.L., Kroeger, P., McWeeny, K., Halbert, D.N., Mollison, K.W., et al. (2002). T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. *Cell. Immunol.* 217, 78–86.
- Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G., and Schoenberger, S.P. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. *Nature* 421, 852–856.
- Jiang, S., Li, C., Olive, V., Lykken, E., Feng, F., Sevilla, J., Wan, Y., He, L., and Li, Q.J. (2011). Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. *Blood* 118, 5487–5497.
- Jin, H.T., Anderson, A.C., Tan, W.G., West, E.E., Ha, S.J., Araki, K., Freeman, G.J., Kuchroo, V.K., and Ahmed, R. (2010). Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proc. Natl. Acad. Sci. USA* 107, 14733–14738.
- Klebanoff, C.A., Gattinoni, L., Palmer, D.C., Muranski, P., Ji, Y., Hinrichs, C.S., Borman, Z.A., Kerkar, S.P., Scott, C.D., Finkelstein, S.E., et al. (2011). Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. *Clinical cancer research: an official journal of the American Association for Cancer Research* 17, 5343–5352.
- Kliver, J., van den Berg, A., de Jong, D., Blokzijl, T., Harms, G., Bouwman, E., Jacobs, S., Poppema, S., and Kroesen, B.J. (2007). Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. *Oncogene* 26, 3769–3776.
- Kurowska-Stolarska, M., Alivernini, S., Ballantine, L.E., Asquith, D.L., Millar, N.L., Gilchrist, D.S., Reilly, J., Ierna, M., Fraser, A.R., Stolarski, B., et al. (2011). MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. *Proc. Natl. Acad. Sci. USA* 108, 11193–11198.
- Li, Q.J., Chau, J., Ebert, P.J., Sylvester, G., Min, H., Liu, G., Braich, R., Manoharan, M., Soutschek, J., Skare, P., et al. (2007). miR-181a is an intrinsic modulator of T cell sensitivity and selection. *Cell* 129, 147–161.
- Louafi, F., Martinez-Nunez, R.T., and Sanchez-Elsner, T. (2010). MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-beta. *J. Biol. Chem.* 285, 41328–41336.
- Lu, L.F., Thai, T.H., Calado, D.P., Chaudhry, A., Kubo, M., Tanaka, K., Loeb, G.B., Lee, H., Yoshimura, A., Rajewsky, K., and Rudensky, A.Y. (2009). Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. *Immunity* 30, 80–91.
- Marine, J.C., Topham, D.J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., Yoshimura, A., and Ihle, J.N. (1999). SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. *Cell* 98, 609–616.
- Marrack, P., and Kappler, J. (2004). Control of T cell viability. *Annu. Rev. Immunol.* 22, 765–787.
- Martinez-Nunez, R.T., Louafi, F., and Sanchez-Elsner, T. (2011). The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). *J. Biol. Chem.* 286, 1786–1794.
- Moskophidis, D., Lechner, F., Pircher, H., and Zinkernagel, R.M. (1993). Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. *Nature* 362, 758–761.
- Mueller, S.N., and Ahmed, R. (2009). High antigen levels are the cause of T cell exhaustion during chronic viral infection. *Proc. Natl. Acad. Sci. USA* 106, 8623–8628.
- Muljo, S.A., Ansel, K.M., Kanellopoulou, C., Livingston, D.M., Rao, A., and Rajewsky, K. (2005). Aberrant T cell differentiation in the absence of Dicer. *J. Exp. Med.* 202, 261–269.
- Murugaiyan, G., Beynon, V., Mittal, A., Joller, N., and Weiner, H.L. (2011). Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. *J. Immunol.* 187, 2213–2221.
- O'Connell, R.M., Rao, D.S., Chaudhuri, A.A., Boldin, M.P., Taganov, K.D., Nicoll, J., Paquette, R.L., and Baltimore, D. (2008). Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. *J. Exp. Med.* 205, 585–594.

- O'Connell, R.M., Kahn, D., Gibson, W.S., Round, J.L., Scholz, R.L., Chaudhuri, A.A., Kahn, M.E., Rao, D.S., and Baltimore, D. (2010). MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. *Immunity* 33, 607–619.
- Ovcharenko, D., Kelnar, K., Johnson, C., Leng, N., and Brown, D. (2007). Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. *Cancer Res.* 67, 10782–10788.
- Overwijk, W.W., Theoret, M.R., Finkelstein, S.E., Surman, D.R., de Jong, L.A., Vyth-Dreese, F.A., Dellemijn, T.A., Antony, P.A., Spiess, P.J., Palmer, D.C., et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8⁺ T cells. *J. Exp. Med.* 198, 569–580.
- Palmer, D.C., and Restifo, N.P. (2009). Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. *Trends Immunol.* 30, 592–602.
- Rodriguez, A., Vigorito, E., Clare, S., Warren, M.V., Couttet, P., Soond, D.R., van Dongen, S., Grocock, R.J., Das, P.P., Miska, E.A., et al. (2007). Requirement of bic/microRNA-155 for normal immune function. *Science* 316, 608–611.
- Salaun, B., Yamamoto, T., Badran, B., Tsunetsugu-Yokota, Y., Roux, A., Baitsch, L., Rouas, R., Fayyad-Kazan, H., Baumgaertner, P., Devevre, E., et al. (2011). Differentiation associated regulation of microRNA expression in vivo in human CD8⁺ T cell subsets. *J. Transl. Med.* 9, 44.
- Salvato, M., Borrow, P., Shimomaye, E., and Oldstone, M.B. (1991). Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. *J. Virol.* 65, 1863–1869.
- Sanjabi, S., Mosaheb, M.M., and Flavell, R.A. (2009). Opposing effects of TGF- β and IL-15 cytokines control the number of short-lived effector CD8⁺ T cells. *Immunity* 31, 131–144.
- Schmid, D.A., Irving, M.B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J.C., Gomez-Eerland, R., Thome, M., Schumacher, T.N., Romero, P., et al. (2010). Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. *J. Immunol.* 184, 4936–4946.
- Seki, Y., Yang, J., Okamoto, M., Tanaka, S., Goitsuka, R., Farrar, M.A., and Kubo, M. (2007). IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. *J. Immunol.* 178, 262–270.
- Shedlock, D.J., and Shen, H. (2003). Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* 300, 337–339.
- Thai, T.H., Calado, D.P., Casola, S., Ansel, K.M., Xiao, C., Xue, Y., Murphy, A., Frenthewey, D., Valenzuela, D., Kutok, J.L., et al. (2007). Regulation of the germinal center response by microRNA-155. *Science* 316, 604–608.
- Tili, E., Michaille, J.J., Cimino, A., Costinean, S., Dumitru, C.D., Adair, B., Fabbri, M., Alder, H., Liu, C.G., Calin, G.A., and Croce, C.M. (2007). Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF- α stimulation and their possible roles in regulating the response to endotoxin shock. *J. Immunol.* 179, 5082–5089.
- Turner, M., and Vigorito, E. (2008). Regulation of B- and T-cell differentiation by a single microRNA. *Biochem. Soc. Trans.* 36, 531–533.
- Ventura, A., Young, A.G., Winslow, M.M., Lintault, L., Meissner, A., Erkeland, S.J., Newman, J., Bronson, R.T., Crowley, D., Stone, J.R., et al. (2008). Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* 132, 875–886.
- Vigorito, E., Perks, K.L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas, S., Das, P.P., Miska, E.A., Rodriguez, A., Bradley, A., et al. (2007). microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. *Immunity* 27, 847–859.
- Wang, P., Hou, J., Lin, L., Wang, C., Liu, X., Li, D., Ma, F., Wang, Z., and Cao, X. (2010). Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. *J. Immunol.* 185, 6226–6233.
- Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R., and Ahmed, R. (2003). Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J. Virol.* 77, 4911–4927.
- Wu, H., Neilson, J.R., Kumar, P., Manocha, M., Shankar, P., Sharp, P.A., and Manjunath, N. (2007). miRNA profiling of naïve, effector and memory CD8 T cells. *PLoS ONE* 2, e1020.
- Xiao, C., and Rajewsky, K. (2009). MicroRNA control in the immune system: basic principles. *Cell* 136, 26–36.
- Xiao, C., Srinivasan, L., Calado, D.P., Patterson, H.C., Zhang, B., Wang, J., Henderson, J.M., Kutok, J.L., and Rajewsky, K. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. *Nat. Immunol.* 9, 405–414.
- Yin, Q., Wang, X., McBride, J., Fewell, C., and Flemington, E. (2008). B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. *J. Biol. Chem.* 283, 2654–2662.
- Zehn, D., Lee, S.Y., and Bevan, M.J. (2009). Complete but curtailed T-cell response to very low-affinity antigen. *Nature* 458, 211–214.
- Zhang, N., and Bevan, M.J. (2010). Dicer controls CD8⁺ T-cell activation, migration, and survival. *Proc. Natl. Acad. Sci. USA* 107, 21629–21634.
- Zhang, N., and Bevan, M.J. (2011). CD8(+) T cells: foot soldiers of the immune system. *Immunity* 35, 161–168.

Supplemental Information

MicroRNA-155 Is Required for Effector CD8⁺

T Cell Responses to Virus Infection and Cancer

Jan C. Dudda, Bruno Salaun, Yun Ji, Douglas C. Palmer, Gwennaëlle C. Monnot, Estelle Merck, Caroline Boudousquie, Daniel T. Utzschneider, Thelma M. Escobar, Rachel Perret, Stefan A. Muljo, Michael Hebeisen, Nathalie Rufer, Dietmar Zehn, Alena Donda, Nicholas P. Restifo, Werner Held, Luca Gattinoni, and Pedro Romero

Supplemental Inventory

Figure S1, Related to Figure 1

Figure S2, Related to Figure 2

Figure S3, Related to Figure 5

Figure S4, Related to Figure 6

Figure S5, Related to Figure 7

Supplemental Figure 1 related to Figure 1A




Figure S1. Early Expression of BIC Is Dependent on TCR Affinity, Related to Figure 1

Expression fold-changes (0-6h) in the levels of BIC (pre-miR-155) non-coding RNA in the panel of primary human CD8⁺ T cells transduced with NY-ESO-1-specific TCRs of increasing affinity following TCR stimulation with NY-ESO-1₁₅₇₋₁₆₅ multimers. Data are from one microarray experiment.

Supplemental Figure 2 related to Figure 2 A-C




Figure S2. miR-155 Independent Acquisition of Effector Functions but Defective Memory Formation, Related to Figure 2

(A) Differentiation markers on naïve, or gp33 and np396 tetramer positive, virus specific CD8⁺ T cells from blood of naïve or day 8 LCMV WE infected wild type (WT) and *Mir155*^{-/-} mice were measured by flow cytometry.

(B) Virus titers were determined in spleens at day 5 of infection.

(C) Lack of virus persistence was confirmed by transferring naïve P14 T cells into mice on day 21 after LCMV infection. Pictured is CD44 expression of gp33-tetramer⁺ host and donor P14 cells at 3 days after the transfer.

(D) Production of indicated cytokines from gp33 tetramer⁺CD8⁺ splenocytes after *in vitro* restimulation with PMA/Ionomycin at day 8 post infection.

(E) Cytotoxic activity of gp33 tetramer⁺CD8⁺ T cells at day 8 after LCMV infection was determined by chromium release assay using peptide-pulsed target cells. Representative results from one out of two experiments are shown.

(F) Phenotype and cytokine production (upon peptide restimulation) of splenic LCMV specific, gp33 tetramer⁺CD8⁺ T cells from infected wild type (WT) and *Mir155*^{-/-} mice was monitored 3 month upon infection. Points are representing single mice and the line is the mean (B, C). Representative results of one out of three independent experiments with three to five mice are pictured.

Supplemental Figure 3 related to Figure 5





Figure S3. Acquisition of Effector Phenotype and IFN- γ Production Upon Vaccination Is Independent of miR-155, Related to Figure 5

Wild type (WT) and *Mir155*^{-/-} OT-1 cells were transferred into WT mice before vaccination.

(A) Upregulation of CD44 as well as (B) IFN- γ production by respective OT-1 cells was measured in draining lymph nodes on day 4 after vaccination upon restimulation. Data are from one representative out of two experiments with three to five mice per group.

(C) GFP marker positive scrambled miR control and miR-155 transduced cells were stained for the indicated activation markers and cytokine receptors before injection into tumor bearing mice.

Supplemental Figure 4 related to Figure 6




Figure S4. miR-155 Does Not Affect Cytokine Receptor Expression in Naïve CD8⁺ T Cells, Related to Figure 6

Naïve (CD44^{low}CD62L^{high}) CD8⁺ T cells from untreated wild type (WT) or *Mir155*^{-/-} mice were stained for indicated cytokine receptors. Representative results from one out of two experiments with three to five mice are shown.

Supplemental Figure 5 related to Figure 7








Figure S5. Elevated SOCS-1 Expression Does not Affect CD8⁺ Effector Phenotype. Downregulation of SOCS-1 by Retroviral shSOCS-1 Transduction, Related to Figure 7

P14 and P14xSOCS-1 transgenic T cells were transferred into wild type mice before infection with LCMV WE. Expression of (A) activation markers on day 8 and (B) Granzyme B on day 7 was monitored on P14 cells from spleen and displayed as mean +/- SEM.

(C) Cytokine production of splenic P14 T cells was measured upon *in vitro* stimulation with gp33 peptide. Representative data from one out of two experiments (N= 3 to 4) are pictured and the line in the last panel represents the mean.

(D) Inhibition of SOCS-1 expression by two different shSOCS-1 constructs was validated by Immunoblot on transduced T cells. shSOCS-1-21 was used for rescue of pSTAT5 generation in *Mir155*^{-/-} cells (Figure 6D).